These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 23700879

  • 1. Evaluation of tumor response to systemic therapy in hepatocellular carcinoma.
    Gafton B, Pârciu S, Murguleţ E, Bălan G.
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1005-10. PubMed ID: 23700879
    [Abstract] [Full Text] [Related]

  • 2. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
    Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E.
    Clin Cancer Res; 2011 Jul 01; 17(13):4504-12. PubMed ID: 21531821
    [Abstract] [Full Text] [Related]

  • 3. Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma.
    Kambadakone A, Baliyan V, Zhu AX.
    Semin Liver Dis; 2017 Aug 01; 37(3):259-274. PubMed ID: 28847036
    [No Abstract] [Full Text] [Related]

  • 4. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
    Lencioni R, Llovet JM.
    Semin Liver Dis; 2010 Feb 01; 30(1):52-60. PubMed ID: 20175033
    [Abstract] [Full Text] [Related]

  • 5. Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads.
    Yeo DM, Choi JI, Lee YJ, Park MY, Chun HJ, Lee HG.
    J Comput Assist Tomogr; 2014 Feb 01; 38(3):391-7. PubMed ID: 24681857
    [Abstract] [Full Text] [Related]

  • 6. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 7. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 8. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV.
    Invest Radiol; 2012 Jan 26; 47(1):11-7. PubMed ID: 21512396
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Jan 26; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 10. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X, Schlemmer HP, Schmidt B, Höh K, Xu K, Ganten TM, Ganten MK.
    Eur J Radiol; 2013 Feb 26; 82(2):327-34. PubMed ID: 23246016
    [Abstract] [Full Text] [Related]

  • 11. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
    Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB, Nemcek AA, Omary R, Salem R.
    JAMA; 2010 Mar 17; 303(11):1062-9. PubMed ID: 20233824
    [Abstract] [Full Text] [Related]

  • 12. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation.
    Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, De Simone P, Filipponi F, Bartolozzi C.
    Radiology; 2010 Apr 17; 255(1):289-300. PubMed ID: 20308465
    [Abstract] [Full Text] [Related]

  • 13. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N, Koscielny S, Chami L, Chebil M, Benatsou B, Roche A, Ducreux M, Malka D, Boige V.
    Radiology; 2011 Jan 17; 258(1):291-300. PubMed ID: 20980447
    [Abstract] [Full Text] [Related]

  • 14. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V.
    Eur J Radiol; 2013 May 17; 82(5):e205-11. PubMed ID: 23273822
    [Abstract] [Full Text] [Related]

  • 15. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma.
    Koda M, Murawaki Y, Mitsuda A, Ohyama K, Horie Y, Suou T, Kawasaki H, Ikawa S.
    Cancer; 2000 Feb 01; 88(3):529-37. PubMed ID: 10649243
    [Abstract] [Full Text] [Related]

  • 16. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I, Scionti A, Mismas V, Masi G, Vivaldi C, Bartolozzi C, Sacco R.
    Oncology; 2014 Feb 01; 86(4):191-8. PubMed ID: 24800837
    [Abstract] [Full Text] [Related]

  • 17. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
    Spira D, Fenchel M, Lauer UM, Claussen CD, Gregor M, Bitzer M, Horger M.
    Acad Radiol; 2011 Jan 01; 18(1):89-96. PubMed ID: 20926315
    [Abstract] [Full Text] [Related]

  • 18. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.
    Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B.
    AJR Am J Roentgenol; 2013 Jul 01; 201(1):80-96. PubMed ID: 23789661
    [Abstract] [Full Text] [Related]

  • 19. Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy.
    Demeria D, Birchall I, Bain VG.
    Can J Gastroenterol; 2007 Aug 01; 21(8):517-8. PubMed ID: 17703252
    [No Abstract] [Full Text] [Related]

  • 20. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
    Kim MJ, Choi JI, Lee JS, Park JW.
    J Gastroenterol Hepatol; 2011 Jul 01; 26(7):1201-6. PubMed ID: 21371120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.